Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Inc., USA has launched Calcium Gluconate Injection USP, a new product, in the US market, which is bioequivalent and therapeutically equivalent to the reference listed drug, Calcium Gluconate Injection, of Fresenius Kabi USA, LLC.

Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals receives U.S. FDA approval for Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray, with the product expected to be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA.

Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd has announced that its 48th Annual General Meeting will be held on September 11, 2026, through video conferencing or other audio-visual means.

Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd sent letters to shareholders whose email addresses are not registered, providing a web link and QR code to access the Integrated Annual Report and Annual General Meeting Notice for FY 2025-26.

Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd has submitted its Business Responsibility and Sustainability Report for Financial Year 2025-26, as required by SEBI regulations.

Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd has announced its 48th Annual General Meeting (AGM) to be held on September 11, 2026, through video conferencing. The AGM will consider and approve the audited standalone and consolidated financial statements for the financial year ended March 31, 2026. The company will also declare a dividend of INR 2.50 per equity share for the same period. The re-appointment of Mrs. Blanche Saldanha as a Non-Executive Director, liable to retire by rotation, will also be considered.

Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd has announced the notice of its 48th Annual General Meeting (AGM) for the financial year 2025-26, to be held on September 11, 2026. The meeting will consider the audited standalone and consolidated financial statements, declare a dividend of INR 2.50 per equity share, and re-appoint a non-executive director and ratify the remuneration of the cost auditor.

Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd has entered into a settlement agreement with Humana for $15.28 million to resolve antitrust and consumer protection lawsuits in the US. The company denies all allegations and the settlement does not constitute any concession or admission of liability.

Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd has allotted 23,863 equity shares under the Employee Stock Option Plan 2016 (ESOP 2016) to a grantee who exercised options. The paid-up capital of the company has increased from Rs. 28,22,00,809 to Rs. 28,22,24,672.

Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd has informed about the schedule of Analyst / Institutional Investor meetings to be conducted on various dates in August and September 2026.

Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd has announced that its 48th Annual General Meeting (AGM) will be held through Video Conferencing (VC) or Other Audio-Visual Means (OAVM) on September 11, 2026. The company has also provided details of the AGM, including the record date, cut-off date for remote e-voting, and the remote e-voting website.

Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd has uploaded the transcript of its earnings call for the quarter ended June 30, 2026, on its website. The call was held on August 3, 2026.

Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd has uploaded the audio recording of its Q1 FY 2026-27 Earnings Call on its website, as per Regulation 30 and 46 of the SEBI (Listing Obligations and Disclosure Requirements), 2015.

Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd has published its unaudited financial results for the quarter ended June 30, 2026, in Financial Express and Loksatta newspapers.

Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd has reported Q1 FY27 results with consolidated revenue of Rs. 40,185 million, a 23.1% YoY growth, driven by broad-based growth across key markets, with India, North America, and Emerging Markets delivering strong performance.

Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd has announced its Q1 FY27 results, with consolidated revenue growing 23.1% YoY to Rs. 40,185 million, driven by strong growth in India, North America, and Emerging Markets. EBITDA was Rs. 8,048 million, with a margin of 20.03%, and PAT was Rs. 4,828 million, with a margin of 11.8%. The company has also highlighted its focus on strengthening its core businesses and expanding its specialty and innovation-led platforms.

Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd has updated the list of officials authorized to determine materiality of events and make disclosures to stock exchanges, as per Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd has announced the record date for dividend for the Financial Year ended March 31, 2026 as August 31, 2026. The company has also approved the financial results for the quarter ended June 30, 2026 and announced the reconstitution of the Risk Management Committee.

Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with revenue from operations at ₹24,349.93 crore and profit before tax at ₹8,661.02 crore.

Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, with annual sales of approximately $1.6 billion in the 12-month period ending May 2026.